Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Lung neoplasms | D008175 | HP_0100526 | C34.90 | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Multiple myeloma | D009101 | — | C90.0 | — | 1 | — | — | — | 1 |
Plasma cell neoplasms | D054219 | — | — | — | 1 | — | — | — | 1 |
Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | — | 1 | — | — | — | 1 |
Drug common name | Tacedinaline |
INN | tacedinaline |
Description | Tacedinaline is a benzamide obtained by formal condensation of the carboxy group of 4-acetamidobenzoic acid with one of the amino groups of 1,2-phenylenediamine. An oral cytostatic drug with impressive differential activity against leukemic cells and normal stem-cells. Also used in combination therapy for selected tumors including non-smoll cell lung, pancreatic, breast, and colorectal cancers. It has a role as an EC 3.5.1.98 (histone deacetylase) inhibitor and an antineoplastic agent. It is a member of acetamides, a member of benzamides and a substituted aniline. It is functionally related to a 1,2-phenylenediamine. |
Classification | Small molecule |
Drug class | narcotic agonists/antagonists (normorphine type) |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CC(=O)Nc1ccc(C(=O)Nc2ccccc2N)cc1 |
PDB | — |
CAS-ID | 112522-64-2 |
RxCUI | — |
ChEMBL ID | CHEMBL235191 |
ChEBI ID | 90195 |
PubChem CID | — |
DrugBank | — |
UNII ID | UMF554N5FG (ChemIDplus, GSRS) |